Neuroprotective composition comprising pyruvate and citrate

By using pyruvate and citrate compositions, the problem of insufficient energy demand for neurons and glial cells in epilepsy seizures is solved, metabolic activity is improved, excitotoxicity and inflammation is reduced, and the progress of epilepsy is delayed, and the progress of epilepsy is achieved. Effective prevention and treatment of epilepsy.

CN119072308APending Publication Date: 2024-12-03NV NUTRICIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036049.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-02
Filing Date
2023-03-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat neuronal damage caused by epilepsy seizures. Especially in epilepsy-like seizures, the energy demands of neurons and glial cells are difficult to meet, resulting in an increase in excitotoxicity and inflammation, which in turn aggravates the worsening of epilepsy. .

Method used

Using a composition containing a therapeutically effective amount of pyruvate and citrate, optimize energy metabolism, reduce excitotoxicity, and prevent neuroinflammatory and epilepsy-like by increasing glycolysis, respiration and ATP production of neurons and glial cells. The formation of circuit.

Benefits of technology

It significantly improves the metabolic activity of neurons and glial cells, reduces excitotoxicity related to epilepsy seizures, prevents the formation of neuroinflammatory and epilepsy-like circuits, delays the progress of epilepsy, and improves the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005099686630000161
    Figure BDA0005099686630000161
  • Figure BDA0005099686630000241
    Figure BDA0005099686630000241
  • Figure HDA0005099686640000011
    Figure HDA0005099686640000011
Patent Text Reader

Abstract

The present invention relates to a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in the treatment and / or prevention of neuronal damage in a subject suffering from or at risk of seizures.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to compositions for use in promoting neuroprotection, particularly in patients at risk for or suffering from epileptic seizures. Background Art

[0002] In subjects with epileptic seizures, brain function is temporarily interrupted due to abnormal excessive or synchronous neuronal activity. Its manifestations may include a period of abnormal behavior, sensations and sometimes loss of consciousness. Epileptic seizures cause mitochondrial release of reactive oxygen species (ROS), causing oxidative stress and cellular macromolecular dysfunction, compromising mitochondrial stability and ultimately producing energy in the form of adenosine triphosphate (ATP). Overall, this increases neuronal excitability and may cause neuronal damage, ultimately leading to glial damage. Neuronal and glial cell death, in turn, triggers abnormal growth of epileptogenic neuronal networks in the brain, which increases the frequency and severity of epileptic seizures and causes behavioral and cognitive impairments, leading to progressive deterioration of epilepsy and ultimately reducing quality of life.

[0003] Under physiological conditions, the brain is an energy-intensive organ, where many processes associated with neuronal and glial function require large amounts of energy in the form of ATP. The brain strongly depends on a continuous supply of glucose. In addition to glucose, neurons are able to oxidize other fuels such as amino acids (mainly glutamate and glutamine), ketone bodies, lactate, and pyruvate. For example, during fasting, ketone bodies serve as an important fuel source, gradually replacing glucose during the transition from fasting to starvation.

[0004] Epilepsy is not always well controlled, whether it is idiopathic (unknown cause), hereditary (genetically transmitted) or acquired (caused by other diseases such as stroke, traumatic brain injury), and the ketogenic diet (KD) shows good anti-epileptic effects in drug-resistant epilepsy. KD is a dietary regimen involving the production of ketone bodies and the induction of nutritional ketosis. KD is a high-fat, low-carbohydrate diet in which ketone body production is promoted by an extreme reduction in carbohydrate intake and the intake of large amounts of fat. The classic KD, consisting of high fat, low protein and low carbohydrates (typically a weight ratio of fat to the sum of protein and carbohydrates of up to 4:1), was first introduced in the 1920s for use in human childhood epilepsy. KD was originally recommended to mimic the metabolic state and biochemical changes associated with fasting, because fasting has been shown to have anticonvulsant properties. It is now known that the ketogenic diet can be used to treat refractory epilepsy and GLUT1 deficiency and to prevent refractory epileptic seizures.

[0005] It has been shown that approximately 50% of patients experience a reduction in seizures after using the KD (Dutton S, Epilepsy, 49:67-9 (2008)). In drug-resistant epilepsy (defined as failure of adequate trials of two anti-epileptic drugs as monotherapy or in combination to achieve sustained seizure freedom), the ketogenic diet reduces seizures by more than 50% in more than 50% of patients, and 15%-25% of these patients can even become seizure-free.

[0006] In subjects on a KD, fatty acids are utilized by fatty acid oxidation in the mitochondria of cells. The brain is normally fueled exclusively by glucose, and lipids in the form of plasma lipoproteins do not themselves cross the blood-brain barrier to any great extent. The liver can use long-chain fatty acids to synthesize three ketone bodies, beta-hydroxybutyrate, acetoacetate, and acetone. These ketone bodies can cross the blood-brain barrier and act as a glucose substitute.

[0007] KD is believed to cause adaptive changes in brain energy metabolism by increasing energy production, and has an effect on neuronal function and neurotransmitter release, as well as the removal of ATP-dependent neurotransmitters from the synaptic cleft and repolarization after excitation. The increase in mitochondrial ATP production transmitted by ketones also contributes to the activation of inhibitory A1 adenosine receptors and further stability of neurons. This is believed to help neurons remain stable in the face of increased energy demand, i.e., a neuroprotective effect. Studies have shown that ketone administration after ischemic injury reduces the effects of ischemic injury on the brain (White and Venkatesh, 2011, Critical Care [Critical Care] 15: 219). In addition, studies have shown that neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease) will benefit from ketone administration (Reger et al., 2004, Neurobiol Aging. [Aging Neurobiology] 25: 31, 1-4).

[0008] Although KD plays a role in preventing and / or treating epileptic seizures (particularly, not only in subjects with epilepsy, but also in other subjects with or at risk of epileptic seizures), there is still a continuing need to prevent and / or treat neuronal damage. Therefore, there is still a need to develop compositions, methods and uses for improving neuroprotection in subjects with or at risk of epileptic seizures. Summary of the invention

[0009] The inventors have observed that neuronal damage is prevented or reduced in subjects suffering from or at risk of epileptic seizures following administration of a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate or derivatives thereof.

[0010] The inventors found that pyruvate increased glycolysis, respiration and ATP production in glial cells under epileptic seizure and ketogenic diet-like conditions, and unexpectedly found that citrate enhanced this effect in a more than additive manner. Therefore, providing pyruvate in combination with citrate synergistically helps neurons and glial cells meet their energy demands during epileptic seizures and provides a neuroprotective effect.

[0011] The inventors have discovered that compositions comprising a therapeutically effective amount of a combination of pyruvate and citrate are useful for treating and / or preventing and / or reducing the severity of neuronal damage by: i) increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rates; ii) reducing and / or preventing excitotoxicity associated with or following epileptic seizures; ii) preventing and / or treating neuroinflammation; iii) preventing and / or delaying the formation of epileptiform circuits in the brain. In other words, the present invention relates to the use of a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate or a derivative thereof for treating and / or preventing neuronal damage in a subject having an epileptic seizure or at risk of an epileptic seizure. The present invention also relates to a method for treating and / or preventing neuronal damage in a subject having an epileptic seizure or at risk of an epileptic seizure, the method comprising administering to the subject a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate or a derivative thereof. In particular, the present invention provides neuroprotective compositions, methods of use, and uses of the neuroprotective compositions for treating and / or preventing neuronal damage in subjects suffering from or at risk of epileptic seizures (preferably epileptic seizures). In a preferred embodiment, the neuroprotective composition is for use in subjects on a ketogenic diet. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The present invention will be discussed in more detail below with reference to the accompanying drawings.

[0013] The present invention will be discussed in more detail below with reference to the accompanying drawings.

[0014] Figure 1 depicts the acute effects of citrate and pyruvate on mitochondrial respiration in resting and hyperexcitable (seizure-like) glial cell cultures.

[0015] Figure 2 Acute effects of citrate and pyruvate on glycolysis in resting and hyperexcitable (seizure-like) glial cell cultures are described.

[0016] Figure 3 Acute effects of citrate on ATP production, mitochondrial respiration, glycolysis, and lactate secretion in resting and hyperexcitable (seizure-like) glial cell cultures are described.

[0017] Figure 4 Chronic effects of citrate on ATP production and mitochondrial respiration in quiescent glial cell cultures are described.

[0018] Figure 5 Chronic effects of citrate on glycolysis and lactate secretion in quiescent glial cell cultures are described.

[0019] Figure 6 The acute effects of pyruvate and the role of citrate on ATP production and mitochondrial respiration in glial cell cultures under epileptic seizure and ketogenic diet-like conditions are described.

[0020] Figure 7 The acute effects of pyruvate and the effects of citrate on glycolysis and lactate secretion in glial cell cultures under epileptic seizure and ketogenic diet-like conditions are described.

[0021] Figure 8 Chronic effects of pyruvate and citrate on ATP production and mitochondrial respiration in glial cell cultures under seizure and ketogenic diet-like conditions and the effects of leucine and nicotinamide riboside on them are described.

[0022] Fig. 9 Chronic effects of pyruvate and citrate on glycolysis and lactate secretion in glial cell cultures under epileptic seizure and ketogenic diet-like conditions are described.

[0023] Fig.10 Chronic effects of citrate on neuronal and glial cell death induced by chronic hyperexcitability are described.

[0024] Fig.11 Chronic effects of pyruvate on neuronal and glial cell death induced by chronic hyperexcitability are described.

[0025] Fig.12 Chronic pre-exposure of glial cell cultures to low excitatory (0.1 mM) Mg 2+ Permanent network changes are produced, characterized by enhanced network excitability and activity.

[0026] Fig.13 Describes switching glial cell cultures from high non-excitatory (0.8 mM) to low excitatory (0.1 mM) Mg 2+ Acute effects of culture medium on basal glycolysis, basal mitochondrial respiration, and basal ATP production.

[0027] List of Examples

[0028] 1. A neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures.

[0029] 2. The neuroprotective composition for use according to clause 1, wherein the treatment and / or prevention of neuronal damage comprises preventing and / or treating neuroinflammation, preventing and / or delaying the formation of epileptiform circuits in the brain.

[0030] 3. A neuroprotective composition for use according to clauses 1 and 2, wherein the treatment and / or prevention of neuronal damage involves increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate.

[0031] 4. A neuroprotective composition for use according to the preceding clause, wherein the treatment and / or prevention of neuronal damage comprises reducing excitotoxicity associated with or following an epileptic seizure.

[0032] 5. A neuroprotective composition for use according to the preceding clause, wherein the subject suffering from or at risk of epileptic seizures is a subject suffering from stroke, traumatic brain injury, migraine, epilepsy, Alzheimer's disease, Parkinson's disease, or a disorder that impairs neuronal and glial energy metabolism, including glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage disease, and mitochondrial disease.

[0033] 6. A neuroprotective composition for use according to the preceding clause, wherein the composition further comprises one or more compounds selected from leucine and nicotinamide riboside.

[0034] 7. A neuroprotective composition for use according to the preceding clause, wherein the subject suffering from or at risk of epileptic seizures is adhered to a ketogenic diet, preferably a ketogenic diet with a ketogenic ratio between 1:1 and 4:1.

[0035] 8. A neuroprotective composition for use according to the preceding clause, wherein the composition is a supplement to a ketogenic diet.

[0036] 9. A neuroprotective composition for use according to the preceding clause, wherein the composition is a supplement to ketogenic tube feeding.

[0037] 10. A neuroprotective composition for use according to clauses 7 to 9, wherein the neuroprotective composition is administered to the subject suffering from or at risk of epileptic seizures and provided with between 0.1 mg and 18 mg citrate in grams citrate / kcal of ketogenic diet and between 15 mg and 25 mg pyruvate / kcal of ketogenic diet.

[0038] 11. The neuroprotective composition for use according to clause 10, further providing nicotinamide riboside in an amount ranging from 0.01 mg to 0.4 mg / kcal of a ketogenic diet, and / or leucine in an amount ranging from 0.02 mg to 30 mg / kcal of a ketogenic diet.

[0039] 12. A neuroprotective composition for use according to the preceding clause, wherein

[0040] Citrate is present in the neuroprotective composition in an amount to provide a daily dosage of 0.01 g to 0.7 g / kg body weight / day;

[0041] Pyruvate is present in the neuroprotective composition in an amount to provide a daily dosage of 0.15 g to 1 g per kg of body weight per day; and

[0042] Optionally, nicotinamide riboside is present in the neuroprotective composition in an amount to provide a daily dosage of 0.5 mg to 15 mg per kilogram of body weight per day;

[0043] And optionally, leucine is present in the neuroprotective composition in an amount to provide a daily dosage of 3 mg to 30 mg per kg body weight per day. DETAILED DESCRIPTION

[0044] The present invention provides neuroprotective compositions, methods and uses for treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures.

[0045] It was found that neuroprotective compositions comprising a combination of therapeutically effective amounts of pyruvate and citrate are useful for use in treating and / or preventing neuronal damage by: i) reducing and / or preventing excitotoxicity associated with or following an epileptic seizure, ii) preventing and / or treating neuroinflammation, and / or iii) preventing and / or delaying the formation of epileptiform circuits in the brain. In some aspects, the neuroprotective composition may optionally further comprise a therapeutically effective amount of nicotinamide riboside and / or leucine. In one aspect, the neuroprotective composition reduces the extent of neuronal damage in the brain.

[0046] The inventors were surprised to observe that compositions comprising pyruvate and citrate increase glycolysis and glycolytic ATP production rates of neurons and glial cells under acute and chronic epileptic seizure conditions. The increase in glycolytic rate in glial cells increases lactate production, thereby maintaining neuronal mitochondrial energy production in neurons under epileptic seizure conditions and under ketogenic conditions. The inventors further observed that both leucine and nicotinamide riboside enhance the gain of respiratory capacity of neurons and glial cells. Providing a composition comprising pyruvate and citrate reduces the death of neurons and glial cells under epileptic seizure conditions. Use it to prevent and / or treat neuroinflammation caused by the death of neurons and glial cells. In addition, compositions comprising pyruvate and citrate prevent and / or delay the formation of abnormal circuit integration and / or epileptiform circuits in the brain. Such abnormal circuit integration and / or the formation of epileptiform circuits are usually the result of glial cell death and subsequent neuroinflammation.

[0047] definition

[0048] In this application, the following terms and abbreviations may be used.

[0049] A classic ketogenic diet contains an amount of lipids (by weight) which may be about 4 times the total weight of protein and digestible carbohydrates. In the context of the present invention, the so-called ketogenic (weight) ratio is the weight ratio of the amount of lipids to the combined weight of protein and digestible carbohydrates in the composition. The ketogenic diet mentioned in the context of the present invention is a dietary intervention which may be any type of ketogenic diet known in the art, preferably characterized in that the ketogenic weight ratio is between 1:1 and 4:1, i.e. the ratio of the amount of fat to the combined amount of protein and digestible carbohydrates. Within the above (sub)ranges of the ketogenic ratio of the present invention, the ketogenic diet used in the context of the present invention preferably contains a lipid weight content at least twice the carbohydrate weight content.

[0050] As used herein, the term "ketosis" preferably refers to a subject with a blood ketone level above 0.5mmol / L. Ketone levels persistently above 0.5mmol / L, and ideally in the range of 1 to 3mmol / L, appear to provide a therapeutic effect in humans [Anderson JC et al. Obes Sci Pract. [Obes Science and Practice] 2021; 7(5): 646-656)]. Therefore, subjects administered the neuroprotective composition of the present invention preferably exhibit ketone levels within the above range. Ketone levels in the blood above 10mmol / L are associated with signs of ketoacidosis. Although ketosis refers to a state of elevated ketones, ketoacidosis is a pathological and potentially life-threatening condition that, among other things, causes a decrease in blood pH and may induce a coma.

[0051] In the context of the present invention, the subject adhering to or taking the neuroprotective composition or ketogenic diet is a mammal, preferably a human. When referring to amounts per kilogram of body weight, this is the body weight of the subject to whom the neuroprotective composition is being used or administered.

[0052] As used herein, the term "seizure" refers to a period of symptoms caused by abnormal excessive or synchronized neuronal activity in the brain. Seizures usually occur when the electrical activity of the brain becomes more "synchronous", such as when a person is in a sleepy state. The most common and typical type of seizure is convulsion (60%). "Convulsion" is a medical condition in which the muscles of the body contract and relax rapidly and repeatedly, resulting in uncontrolled shaking. Epileptic seizures can include convulsions. Epilepsy is a clinical diagnosis characterized by recurrent seizures, which are the outward manifestation of abnormal electrical activity of neurons in the cerebral cortex that is excessive and / or hypersynchronous.

[0053] As used herein, "excitotoxicity" refers to the excessive release or abnormal accumulation of excitatory neurotransmitters (such as glutamate) in synapses. Glutamate-induced excitotoxicity causes neuronal death, which is caused by the continued electrical excitation of neurons during epileptic seizures, and increased glutamate levels are observed in epileptic human brain tissue. Seizures caused by epilepsy, head trauma, or neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)) involve excessive release of excitatory neurotransmitters and may cause neuronal death or permanent damage due to excitotoxicity.

[0054] As used herein, the term "supplement" or "dietary supplement" refers to a nutritional product that provides nutrients to an individual who may not otherwise be able to conveniently take in sufficient amounts of these nutrients. Supplements typically provide selected nutrients, but do not represent a significant portion of the overall nutritional needs of the subject. Typically, they do not represent more than 0.1%, 1%, 5%, 10% of the daily energy requirements of the subject.

[0055] As used herein, derivatives include food-approved complexes or salts of pyruvate and citrate. Derivatives of pyruvate and citrate according to the present invention include physiologically acceptable complexes, acids or salts thereof, such as calcium salts, potassium salts, sodium salts, magnesium salts, ammonium salts and conjugate acids (pyruvic acid and citric acid). In embodiments, derivatives of pyruvate and citrate according to the present invention may include food-approved esters. When the terms pyruvate and citrate are used, derivatives of the molecules are encompassed herein.

[0056] In this document and its claims, the verb "comprise" and its variations are used in their non-limiting sense, meaning that the items following the word are included, but items not specifically mentioned are not excluded. Furthermore, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that one and only one of the element is present. Thus, the indefinite article "a" or "an" generally means "at least one".

[0057] Neuronal damage in subjects with or at risk for epileptic seizures

[0058] In one aspect of the invention, a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate or a derivative thereof is for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein the subject suffers from a condition selected from the group consisting of:

[0059] i) neurological disorders, including stroke, traumatic brain injury, migraine, epilepsy,

[0060] ii) neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, age-related mild cognitive impairment, or

[0061] iii) Disorders that impair neuronal and glial energy metabolism, including glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases.

[0062] In a preferred aspect, the neuroprotective composition is for use in preventing neuronal damage in a subject with refractory epilepsy.The subject may be refractory to anti-epileptic drugs or a ketogenic diet, or a combination of both.

[0063] In a preferred embodiment, a subject suffering from epileptic seizures or at risk of epileptic seizures takes a ketogenic diet. In one aspect, the ketogenic diet can be selected from a classic ketogenic diet, an MCT diet, a modified Atkins diet, and a low glycemic index therapeutic diet. Preferably, the ketogenic diet has a ketogenic ratio between 1:1 and 4:1. The subject is a human subject in need of ketosis treatment.

[0064] In a further preferred embodiment, a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate or derivatives thereof is for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein the subject is treated with a ketogenic diet for a neurological disorder selected from stroke, traumatic brain injury, migraine, epilepsy, Alzheimer's disease, Parkinson's disease, or a disorder that impairs neuronal and glial energy metabolism, including glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases, and mitochondrial diseases.

[0065] Neuroprotective composition ingredients

[0066] Citrate

[0067] The neuroprotective composition comprises a therapeutically effective amount of citrate and / or its derivatives. Citrate (including conjugate acid) is present in the neuroprotective composition in a therapeutically effective amount to treat and / or prevent neuronal damage. The citrate used in the neuroprotective composition can be citric acid or potassium salt (K + ), sodium salt (Na + ), magnesium salt (Mg 2+ ) or calcium salt (Ca 2+ ) in the form of.

[0068] Citrate, or citric acid, is converted to isocitrate in the first step of the Krebs cycle (also known as the citric acid or TCA cycle). Citrate was found to unexpectedly increase the rate of glycolysis in an in vitro glial cell model.

[0069] In an embodiment, citrate is present in a neuroprotective composition in a therapeutically effective amount to treat and / or prevent neuronal damage by increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate. In one aspect of the invention, citrate i) reduces and / or prevents excitotoxicity associated with or following an epileptic seizure, ii) prevents and / or treats neuroinflammation, iii) prevents and / or delays the formation of epileptiform circuits in the brain.

[0070] On the other hand, citrate treats and / or prevents neuronal damage by increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate. In one aspect of the invention, citrate and pyruvate together i) reduce and / or prevent excitotoxicity associated with or after epileptic seizures, ii) prevent and / or treat neuroinflammation, iii) prevent and / or delay the formation of epileptiform circuits in the brain. In an embodiment, the formation of overexcited epileptic neuronal networks is prevented. In one aspect of the invention, the effects of citrate and pyruvate are synergistic.

[0071] Citrate is preferably present in the neuroprotective composition in an amount to provide a daily dosage of citrate in the range of 0.01 g to 0.7 g / kg body weight / day, preferably 0.05 g to 0.3 g / kg body weight / day, more preferably 0.08 g to 0.1 g / kg body weight / day.

[0072] On the other hand, a neuroprotective composition is used and used with a ketogenic diet. Citrate is preferably present in the neuroprotective composition in a range of 0.1 mg to 17 mg citrate / kcal ketogenic diet, more preferably 0.5 mg to 12 mg citrate / kcal ketogenic diet, and even more preferably 1 mg to 8 mg citrate / kcal ketogenic diet. Citrate is preferably present in the neuroprotective composition in a dosage corresponding to 0.05 wt% to 10 wt% of the total weight of the ketogenic diet, more preferably 0.3 wt% to 5 wt% of the total weight of the ketogenic diet. Any amount of citrate equivalents or derivatives is recalculated as the amount of the equivalent weight of citrate, excluding counterions.

[0073] The weight range and percentage of citrate in the neuroprotective composition associated with a ketogenic diet is based on a daily intake between 500 and 4000 kcal / day and a body weight between 5 kg and 100 kg.

[0074] A daily intake of less than 15 g / day of citrate for K+ / Na+ / Mg2+-citrate and possibly less than 20 g / day for Ca2+-citrate is considered safe and does not cause the risk of electrolyte imbalance.

[0075] Pyruvate

[0076] The neuroprotective composition comprises a therapeutically effective amount of pyruvate. Pyruvate (including the conjugate acid) is present in the neuroprotective composition in a therapeutically effective amount to treat and / or prevent neuronal damage.

[0077] As used herein, the term "pyruvate" encompasses precursors of pyruvic acid and pyruvate and pyruvate, particularly precursors that can release pyruvic acid or pyruvate by in vivo conversion (e.g., hydrolysis) of precursor molecules. A typical example of a pyruvate precursor that can be hydrolyzed to produce pyruvate (pyruvate or pyruvate salt) is a pyruvate ester. Pyruvate can be incorporated, for example, as a free acid or as its Ca salt, Na salt, or K salt.

[0078] "It is known that pyruvate is the end product of the glycolytic pathway. Astrocytes convert pyruvate into lactate and provide lactate to neurons, which then serves as a substrate for mitochondrial ATP production. We now find that pyruvate unexpectedly increases the rate of glycolysis in an in vitro glial cell model, thereby increasing ATP production overall."

[0079] In an embodiment, pyruvate is present in a neuroprotective composition in a therapeutically effective amount to treat and / or prevent neuronal damage by increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate. In one aspect of the invention, pyruvate i) reduces and / or prevents excitotoxicity associated with or following an epileptic seizure, ii) prevents and / or treats neuroinflammation, iii) prevents and / or delays the formation of epileptiform circuits in the brain.

[0080] On the other hand, pyruvate treats and / or prevents neuronal damage by increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate. In one aspect of the invention, the combination of citric acid and pyruvate i) reduces and / or prevents excitotoxicity associated with or following epileptic seizures, ii) prevents and / or treats neuroinflammation, and / or iii) prevents and / or delays the formation of epileptiform circuits in the brain. In an embodiment, the formation of overexcited epileptic neuronal networks is prevented. In one aspect of the invention, the effects of citric acid and pyruvate are synergistic.

[0081] Pyruvate is preferably present in the neuroprotective composition in an amount to provide a daily dosage of pyruvate in the range of 0.15 g to 1 g / kg body weight / day, preferably 0.3 g to 0.6 g / kg body weight / day, more preferably 0.4 g to 0.5 g / kg body weight / day.

[0082] On the other hand, neuroprotective compositions can be used and used with a ketogenic diet. Pyruvate is preferably present in the neuroprotective composition in a range of 1.5 mg to 25 mg pyruvate / kcal ketogenic diet, more preferably 2.5 mg to 15 mg pyruvate / kcal ketogenic diet, and even more preferably 5.8 mg to 12 mg pyruvate / kcal ketogenic diet. Pyruvate is preferably present in the neuroprotective composition in a dosage corresponding to 1 wt% to 13 wt% of the total weight of the ketogenic diet, more preferably 1.5 wt% to 9 wt% of the total weight of the ketogenic diet. Any amount of pyruvate equivalents or derivatives is recalculated as the amount of the equivalent weight of pyruvate, excluding counterions.

[0083] The weight range and percentage of pyruvate in the neuroprotective composition associated with a ketogenic diet is based on a daily intake between 500 and 4000 kcal / day and a body weight between 5 kg and 100 kg.

[0084] Nicotinamide riboside

[0085] The present invention provides a neuroprotective composition optionally further comprising a therapeutically effective amount of an NAD+ precursor selected from the group consisting of: tryptophan, nicotinic acid (nicotinic acid), nicotinamide (nicotinamide or NAM), nicotinic acid riboside (NaR), nicotinamide riboside (NR), and mixtures thereof. In a preferred aspect, the neuroprotective composition may comprise nicotinamide riboside (NR). Any amount of NAD+ precursors is recalculated as an amount of equivalent weight of nicotinamide riboside (NR), and these precursors are selected from the group consisting of: tryptophan, nicotinic acid (nicotinic acid), nicotinamide (nicotinamide or NAM), nicotinic acid riboside (NaR), nicotinamide riboside (NR), and mixtures thereof.

[0086] As used herein, "nicotinamide riboside" includes derivatives thereof, such as L-valine and L-phenylalanine esters of nicotinamide riboside.

[0087] In an embodiment, there is thus provided a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in treating and / or preventing neuronal damage in a subject having or at risk of epileptic seizures, wherein the neuroprotective composition further comprises a therapeutically effective amount of nicotinamide riboside.

[0088] In embodiments, when nicotinamide riboside is present in the neuroprotective composition, the nicotinamide riboside is present in a therapeutically effective amount to treat and / or prevent neuronal damage in a subject having or at risk for epileptic seizures.

[0089] Nicotinamide riboside is preferably present in the neuroprotective composition in an amount to provide a daily dosage of nicotinamide riboside in the range of 0.5 to 15 mg / kg body weight / day, preferably 1.5 to 4.5 mg / kg body weight / day, more preferably 2.5 to 3.5 mg / kg body weight / day.

[0090] On the other hand, a neuroprotective composition can be used and used with a ketogenic diet. Nicotinamide riboside (when present) is preferably present in the neuroprotective composition in a range of 0.01 mg to 0.4 mg nicotinamide riboside / kcal ketogenic diet, more preferably 0.015 mg to 0.25 mg nicotinamide riboside / kcal ketogenic diet, even more preferably 0.02 mg to 0.1 mg nicotinamide riboside / kcal ketogenic diet. Nicotinamide riboside is preferably present in the neuroprotective composition in a dosage corresponding to 0.005 wt% to 0.25 wt% of the total weight of the ketogenic diet, more preferably 0.01 wt% to 0.1 wt% of the total weight of the ketogenic diet.

[0091] Leucine

[0092] The present invention provides a neuroprotective composition, which optionally further comprises a therapeutically effective amount of leucine. In the context of the present invention, the terms "leucine" and "L-leucine" are used interchangeably. In specific embodiments, the neuroprotective composition comprises leucine in the form of a free acid or a salt.

[0093] In embodiments, when leucine is present in the neuroprotective composition, the leucine is present in a therapeutically effective amount to treat and / or prevent neuronal damage in a subject having or at risk for epileptic seizures.

[0094] In an embodiment, there is therefore provided a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein the neuroprotective composition optionally further comprises nicotinamide riboside and / or leucine.

[0095] Leucine is preferably present in the neuroprotective composition in an amount providing a daily dosage in the range of 3 mg to 30 mg / kg body weight / day, preferably 10 mg to 25 mg / kg body weight / day, more preferably 15 mg to 20 mg / kg body weight / day. The above amounts apply to all leucine provided by the composition, including free leucine.

[0096] In another aspect, a neuroprotective composition can be used and used with a ketogenic diet. Leucine is preferably present in the neuroprotective composition in a range of 0.2 mg to 30 mg leucine / kcal ketogenic diet, more preferably 1 mg to 20 mg leucine / kcal ketogenic diet, and even more preferably 0.15 mg to 10 mg leucine / kcal ketogenic diet. Leucine is preferably present in the neuroprotective composition in a dosage corresponding to 0.02 wt% to 3 wt% of the total weight of the ketogenic diet, more preferably 0.1 wt% to 2 wt% of the total weight of the ketogenic diet.

[0097] Neuroprotective compositions

[0098] In an embodiment, therefore, there is provided a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein

[0099] The citrate salt is present in an amount to provide a daily dosage of 0.01 g to 0.7 g / kg body weight / day;

[0100] Pyruvate is present in an amount to provide a daily dosage of 0.15 g to 1 g / kg body weight / day;

[0101] Optionally nicotinamide riboside is present in an amount to provide a daily dosage of 0.5 mg to 15 mg per kilogram of body weight per day;

[0102] And wherein optionally leucine is present in an amount to provide a daily dosage of 3 mg to 30 mg per kg body weight per day.

[0103] In another embodiment, a neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate is provided for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein the subject suffering from or at risk of epileptic seizures adheres to a ketogenic diet, and wherein in the neuroprotective composition

[0104] Citrate is provided in an amount ranging from 0.1 mg to 17 mg citrate / kcal in a ketogenic diet.

[0105] Pyruvate is provided in amounts ranging from 1.5 mg to 25 mg pyruvate / kcal in a ketogenic diet.

[0106] Optionally nicotinamide riboside is provided in an amount within the range of 0.01 mg to 0.4 mg / kcal of a ketogenic diet,

[0107] And optionally leucine is present in the range of 0.02 mg to 30 mg / kcal of the ketogenic diet.

[0108] In preferred aspects, nicotinamide and / or leucine are not optional and are present in the neuroprotective composition.

[0109] The weight ranges and percentages of the neuroprotective composition associated with a ketogenic diet are based on a daily intake between 500 and 4000 kcal / day and a body weight between 5 kg and 100 kg.

[0110] In one aspect of the invention, a kit comprising a neuroprotective composition and a ketogenic diet may be provided. In a preferred aspect, a kit comprising a neuroprotective composition and a ketogenic diet is provided for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures, wherein the subject suffering from or at risk of epileptic seizures adheres to a ketogenic diet. Thus, a kit is provided, comprising 1) a neuroprotective composition and 2) one or more nutritional products having a ketogenic ratio between 1:1 and 4:1.

[0111] Neuroprotective composition administration form

[0112] The neuroprotective compositions of the present invention may be in any form suitable for enteral, oral or parenteral administration. Non-limiting examples of parenteral administration include intravenous, intramuscular, intraperitoneal, subcutaneous, intraarticular, intrasynovial, intraocular, intrathecal, topical and inhalation. In a preferred embodiment, the neuroprotective composition is in a form suitable for oral administration.

[0113] In one aspect of the invention, the composition according to the invention may be used as a pharmaceutical product comprising one or more pharmaceutically acceptable carrier materials.

[0114] The neuroprotective composition according to the invention can be used as a nutritional product, for example as a nutritional supplement, for example as an additive to a ketogenic diet, as a fortifier to be added to a ketogenic diet.

[0115] Preferably, the supplement for enteral application can be solid or liquid galenic formulations. Examples of solid galenic formulations are tablets, capsules (e.g., hard or soft shell gelatin capsules), pills, sachets, powders, granules, etc., which contain active ingredients and conventional galenic carriers. Any conventional carrier material can be used. The carrier material can be an organic or inorganic inert carrier material suitable for oral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, etc. In addition, additives such as flavorings, preservatives, stabilizers, emulsifiers, buffers, etc. can be added according to the recognized practice of nutrition and drug compounding.

[0116] The neuroprotective composition according to the invention may also be used as a nutritional product for use or co-administration with tube feeding, for example as an additive to tube feeding for intermittent or continuous administration.

[0117] The neuroprotective composition may contain a daily dose in one or more dosage units. The dosage unit may be in liquid form or solid form, wherein in the latter case, the daily dose may be provided by one or more solid dosage units, for example in one or more capsules or tablets. The neuroprotective composition may be administered simultaneously with the ketogenic diet, or separately or continuously at time intervals.

[0118] In an embodiment, the administration of the neuroprotective composition is at least daily; for example, the subject may receive one or more doses per day, preferably 1 to 6 times per day, more preferably 3 to 4 times per day. In some embodiments, the administration continues for the remaining life span of the individual. The ideal duration of composition administration can be determined by a person skilled in the art.

[0119] In one aspect, neuroprotective compositions are particularly useful in combination with 80:20C10:C8 triglyceride compositions.

[0120] Additionally, a kit is provided, the kit comprising a neuroprotective composition and a ketogenic diet.

[0121] The invention has been described above with reference to a number of exemplary embodiments shown in the accompanying drawings. Modifications and alternative implementations of some components or elements are possible and are included within the scope of protection defined in the appended claims.

[0122] Examples

[0123] For a more complete understanding of the present disclosure, reference is now made to the following examples in conjunction with the accompanying drawings.

[0124] Example 1

[0125] In the hippocampal assay described below, pyruvate was found to increase glycolysis, respiration, and ATP production in glial cells under seizure-like and ketogenic diet-like conditions, and citrate enhanced this effect in a more than additive manner. Thus, providing pyruvate in combination with citrate synergistically helps neurons and glial cells meet their energy demands during seizure-like seizures and provides a neuroprotective effect.

[0126] Hippocampal assays were performed on primary rat neuron-glial cell cultures to determine the effects of pyruvate and citrate on glycolytic rate and lactate delivery, mitochondrial respiration, and total (glycolytic and mitochondrial) ATP production.

[0127] Primary glial cell culture

[0128] Rat cortical cells were isolated from embryos of embryonic day 18 using a combination of enzymatic and mechanical dissociation of cerebral cortical rat tissue. Immediately after dissociation, cells were seeded in 96-well plates at a density of 500'000 cells / mL and grown for two weeks at 37°C from day 0 in vitro (day in vitro, DIV) until DIV14 in a neurobasal medium supplemented with 2% (v / v) B27, 0.8mM magnesium (Mg2+), 25mM glucose, and 1% (v / v) penicillin / streptomycin. During this period, neuronal axons grew out and formed synaptic contacts. In addition, glial cells (mainly astrocytes) grew and formed contacts with neurons. Incubation in 25mM glucose accelerated the differentiation and network growth of neurons.

[0129] From DIV14 to DIV17, cells were incubated in neurobasal medium supplemented with 2% (v / v) B27, 0.8 mM Mg2+, 5 mM glucose and 1% (v / v) penicillin / streptomycin. High glucose was switched to low glucose to approximate the low intracerebral glucose concentration of the human brain and create a more physiological metabolic environment.

[0130] At DIV17, the culture medium was changed to medium supplemented with 0.1 mM Mg 2+ , 1 mM glucose, and a range of test nutrient concentrations in an unbuffered Hanks' Balanced Salt Solution (HBSS) (a nutrient-deprived medium). 5 mM was switched to 1 mM glucose to match the glucose concentration in the human brain. At the same time, high (0.8 mM) Mg was switched to low (0.1 mM) Mg 2+ Increased neuronal firing rate because Mg2+ is an inhibitor of excitatory NMDA-type ionotropic glutamate receptors (these receptors are responsible for most neuronal firing in this cell culture model). 2+ The increase in neuronal firing caused by incubation in nutrient-rich media resulted in increased energy production in neurons and glial cells, as reflected by an increase in basal respiration (Figure 1B and 1E). The oxygen consumption rate [OCR] and extracellular acidification rate [ECAR] of glial cell cultures were measured in the hippocampal assay after 1 h of preincubation in hippocampal media containing nutrients.

[0131] Hippocampal assay

[0132] The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of cells seeded in 96-well plates were monitored in real time in unbuffered Hanks' balanced salt solution (HBSS) at 37°C. The OCR mainly represents mitochondrial respiration and, to a lesser extent, non-mitochondrial respiration. The ECAR mainly involves the acidification of the culture medium by lactate produced by glycolysis and secreted into the culture medium by the cells (Table 1).

[0133] During the hippocampal run, the hippocampus instrument measured both OCR and ECAR at baseline and after compound injection (Table 1). HBSS was supplemented with glucose from the beginning, and glucose was not injected through the hippocampus instrument. The measurement was repeated three times at baseline and three times after each compound injection.

[0134] Table 1. Compounds used during the hippocampal assay and their effects on oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).

[0135]

[0136] Hippocampus – OCR-oligomycin-mitochondrial ATP synthesis

[0137] After the initial baseline measurement, oligomycin (OM) was injected. OM blocks mitochondrial ATP synthase (complex V) and therefore reduces mitochondrial respiration. The OCR after OM injection is due to mitochondrial proton leak. They can determine whether the test nutrients affect proton leak. The difference in OCR at baseline and after OM injection is the amount of oxygen used for mitochondrial ATP synthesis at baseline. According to this difference in OCR, the mitochondrial ATP production rate is calculated.

[0138] Hippocampus – OCR – FCCP – Maximum respiratory capacity

[0139] After OM, the uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone [FCCP] is injected, which disrupts the proton gradient across the mitochondrial inner membrane that is established during respiration and required for ATP synthesis. The cells attempt to restore the proton gradient after FCCP injection by maximizing respiration. Therefore, the OCR measured after FCCP injection represents the maximal respiratory capacity of the mitochondria in the sample and enables determination of whether the test nutrient affects the maximal respiratory capacity of the mitochondria.

[0140] Hippocampus - OCR - Antimycin A and Rotenone - Non-mitochondrial respiration

[0141] Finally, co-injection of antimycin A (a complex III inhibitor) and rotenone (a complex I inhibitor), both of which block the respiratory chain at different sites, was necessary to completely shut down mitochondrial respiration and determine non-mitochondrial respiration. The latter was necessary to correct all OCRs and obtain mitochondrial OCRs.

[0142] Hippocampus-ECAR

[0143] ECAR is measured at the baseline and after OM and FCCP injection. Glycolytic ATP is produced according to the baseline ECAR. Subsequently, OM is injected to promote cells to maximize their glycolytic ATP production to compensate for the loss of mitochondrial ATP production caused by OM. Further addition of FCCP maximizes mitochondrial respiration, and this ultimately leads to a further increase in the glycolytic rate, thereby providing pyruvate to the TCA cycle to maintain maximum respiration. Therefore, the ECAR after FCCP injection is used to determine the maximum glycolytic capacity of the cell.

[0144] I. Hippocampus - Low Mg2+ - Seizure-like Conditions

[0145] Glial cell cultures were prepared as described above and assayed from DIV0 to DIV14. They were switched to unbuffered Hanks' balanced salt solution (HBSS) supplemented with 5 mM glucose, 2 mM glutamine, 0.1 mM or 0.8 mM Mg2+, and 1 mM citrate one hour before hippocampal run. Switching the medium from high (0.8 mM) Mg2+ to low (0.1 mM) Mg2+ increased the firing frequency of neurons ( Fig.12 The increase in neuronal firing caused by incubation in 0.1 mM Mg2+ medium produced an epileptic seizure-like state and increased the energy demand and production of neurons and glial cells ( Fig.13 This is achieved through increased mitochondrial and glycolytic ATP production ( Fig.13 A) Increase in respiration at baseline ( Fig.13 B) and an increase in glycolysis ( Fig.13 E), and oligomycin-driven increases in glycolytic capacity ( Fig.13 F). Switching from high (0.8 mM) to low (0.1 mM) Mg2+ medium immediately before the hippocampus run dramatically increased the glycolytic rate by approximately 10%-15% over baseline ( Figure 2 A) and increased by about 30%-40% after FCCP injection ( Figure 2 C).

[0146] After 1 h preincubation in Seahorse medium containing the test nutrients, OCR and ECAR were measured as described for the Seahorse assay. Cells were left in this medium until the end of the run.

[0147] Acute effects of pyruvate in seizure-like conditions

[0148] In the first set of experiments, the acute (or immediate) effects of pyruvate were tested in glial cell cultures that were acutely switched from high Mg2+ medium to low Mg2+ medium, i.e., under conditions of enhanced neural excitability or seizure-like conditions. Compared with low Mg2+ medium without pyruvate, the addition of 0.25mM and 1mM pyruvate to low Mg2+ medium further increased the total (mitochondrial and glycolytic) ATP production rate by about 400%-500% (Figure 1A), basal respiration by about 30%-40% (Figure 1B), and FCCP-driven maximum respiratory capacity by about 200%-250% (Figure 1D), but moderately increased oligomycin-induced proton leak by about 10%-15% (Figure 1C). Therefore, pyruvate sharply increased the basal mitochondrial respiration, basal glycolysis and mitochondrial ATP production, and maximum respiratory capacity of neurons and glial cells under seizure-like conditions.

[0149] Furthermore, acute (or immediate) addition of 0.25 mM and 1 mM pyruvate to low Mg2+ medium further increased the glycolytic rate by approximately 15%-20% above baseline compared to low Mg2+ medium without pyruvate addition ( Figure 2 A), and increased by about 20%-30% after FCCP injection ( Figure 2 C).

[0150] Thus, pyruvate acutely increases basal and maximal glycolytic rates and lactate secretion in glial cell cultures under enhanced neural excitability or seizure-like conditions.

[0151] Acute effects of citrate under normal and seizure-like conditions

[0152] Resting condition - OCR

[0153] In a second set of experiments, the acute or immediate effects of citrate were tested in resting glial cell cultures incubated in high Mg2+ medium (nutrient-rich DMEM containing 5 mM glucose). Compared with incubation in control medium without citrate, the addition of citrate dose-dependently increased the mitochondrial oxygen consumption rate (OCR) by up to about 25% at baseline (Figure 1E) and modestly increased OM-induced proton leak by up to about 10% (Figure 1F), but did not significantly affect the FCCP-driven maximal respiratory capacity of the cells (Figure 1G).

[0154] Resting condition - ECAR

[0155] Furthermore, acute (or immediate) addition of citrate dose-dependently increased basal glycolytic rate and lactate secretion by approximately 25% ( Figure 2D). In addition, acute (or immediate) addition of 0.25 mM citrate increased the maximum glycolytic capacity induced by OM and FCCP by approximately 10%-15% ( Figure 2 E, Figure 2 F).

[0156] Thus, citrate provision dramatically increased baseline mitochondrial respiration and basal and maximal glycolytic capacity in neurons and glia under resting conditions.

[0157] Seizure-like conditions - OCR

[0158] Subsequently, the acute (or immediate) effects of citrate on mitochondrial respiration and glycolysis were also assessed in low Mg2+ medium (i.e., under enhanced neural excitability or seizure-like conditions) and compared to incubation in high Mg2+ medium (i.e., under resting conditions). Addition of 1 mM citrate to the medium increased total (mitochondrial and glycolytic) ATP production by approximately 60% in 0.1 mM Mg2+ control medium and by approximately 75% in 0.8 mM Mg2+ control medium ( Figure 3 A). In addition, basal mitochondrial respiration was increased by about 40% in the 0.1 mM Mg2+ control medium and by about 100% in the 0.8 mM Mg2+ control medium ( Figure 3 B). When Mg2+ concentration was switched from 0.8 mM to 0.1 mM, basal ATP production and basal oxygen consumption rates increased, consistent with increased energy demand due to increased neuronal firing. Panel B was corrected for non-mitochondrial oxygen consumption determined by addition of rotenone and antimycin A. n = 5 replicates / condition.

[0159] Thus, citrate acutely increased total ATP production and mitochondrial respiration in glial cell cultures both at rest and under conditions of enhanced neural excitability or seizure-like conditions.

[0160] Epileptic seizure-like conditions - ECAR

[0161] Furthermore, ECAR measurements showed that the addition of 1 mM citrate increased the basal glycolytic rate by approximately 20% in 0.1 mM Mg2+ medium and by approximately 70% in 0.8 mM Mg2+ medium ( Figure 3 C). In addition, the addition of 1 mM citrate tended to increase the OM-induced glycolysis rate by about 15% in 0.1 mM Mg2+ medium and by about 60% in 0.8 mM Mg2+ medium ( Figure 3 D). Finally, 1 mM citrate also tended to increase the maximum glycolytic capacity driven by FCCP by about 35% over that in the 0.8 mM Mg2+ control medium ( Figure 3E) Thus, citrate tends to acutely increase the glycolytic rate and lactate secretion of glial cell cultures both at rest and under conditions of enhanced neural excitability or seizure-like conditions.

[0162] Overall, Figure 3 The results in the literature suggest that citrate increases basal mitochondrial and glycolytic ATP production and basal mitochondrial respiration in the presence of high (0.8 mM) Mg 2+ Low (0.1 mM) Mg in culture medium and induction of epilepsy 2+ In addition, citrate tended to increase basal and maximal glycolytic rates and lactate secretion, indicating that citrate enables glial cells to meet the sudden energy demands caused by acute electrical overstimulation or epileptiform seizures. These results overall suggest that during epileptic seizures, when neurons and glial cells have higher energy demands, this demand can be better met by supplementation with pyruvate and citrate.

[0163] The finding that both pyruvate and citrate increased glycolysis at rest and under conditions of enhanced neural excitability or seizure-like conditions was highly unexpected. Pyruvate is the end product of glycolysis, and its accumulation should reduce the rate of glycolysis. At the same time, citrate is a known physiological inhibitor of glycolysis because it inhibits various tissue-specific and brain-specific isoforms of the rate-limiting enzyme of the glycolytic pathway, called phosphofructokinase 1 (PFK1), at concentrations above 100 μM.

[0164] II. 24-hour effects of citrate under resting conditions

[0165] In addition, the effect of incubation with citrate for 24 h on glycolysis, mitochondrial respiration, and total (glycolytic and mitochondrial) energy (ATP) production under resting conditions was evaluated. Glial cell cultures were grown from DIV0 to DIV14 in neurobasal medium (NBM) supplemented with B27, high (25 mM) glucose, and high (0.8 mM) Mg2+. From DIV14 to DIV16, they were switched to medium supplemented with B27, low (5 mM) glucose, and high (0.8 mM) Mg2+. 2+ At DIV16, the medium was changed to NBM containing low (5 mM) glucose, high (0.8 mM) Mg 2+ and 500 μM or 1 mM citrate in DMEM (not a nutrient-deprived medium, unlike HBSS). At DIV17, one hour before hippocampal operation, cells were incubated with DMEM containing low (5 mM) glucose, high (0.8 mM) Mg 2+ The medium was replaced with unbuffered DMEM containing 500 μM or 1 mM citrate. The cells were kept in this medium until the end of the run. Each condition was repeated five times.

[0166] Citrate-OCR

[0167] Compared with control medium, the addition of 500 μM and 1 mM citrate to the medium increased basal mitochondrial and glycolytic ATP production by approximately 45% ( Figure 4 A). In addition, basal mitochondrial respiration was increased by approximately 60% compared to control culture medium ( Figure 4 B), and compared with the control medium, the maximum mitochondrial respiratory capacity induced by FCCP increased by about 60%-70% ( Figure 4 C). Thus, long-term incubation with citrate for 24 hours increased total ATP production, baseline and maximal mitochondrial respiration in quiescent glial cell cultures. Panels B and C were corrected for non-mitochondrial oxygen consumption determined by the addition of rotenone and antimycin A.

[0168] Citrate-ECAR

[0169] ECAR measurements performed simultaneously with OCR measurements showed that the addition of 500 μM and 1 mM citrate to the culture medium increased the basal glycolytic rate by approximately 45% and approximately 20%, respectively, compared to the control culture medium ( Figure 5 In addition, compared with the control medium, OM-induced glycolysis rate increased by about 70% and about 30%, respectively ( Figure 5 B). Finally, compared with the control medium, the maximum glycolytic capacity induced by FCCP was increased by about 75% and about 50% ( Figure 5 C) Thus, prolonged incubation with citrate for 24 h increased basal and maximal glycolytic rates and lactate secretion in quiescent glial cell cultures.

[0170] Therefore, incubation in citrate for 24 h resulted in basal (glycolytic and mitochondrial) ATP production ( Figure 4 A), basal and maximal mitochondrial respiration ( Figure 4 B, Figure 4 C), basal and maximal glycolytic rates and lactate secretion ( Figure 5 )Increase.

[0171] Figure 4 and 5 The results presented in demonstrate that during epileptic seizures, when neurons and glia have a higher energy demand, this demand can be better met by supplementation with pyruvate and citrate. Furthermore, the effect of pyruvate is independent of other nutrients, as its effect is seen in nutrient-poor HBSS medium, while the sole effect of citrate is only seen in nutrient-rich DMEM, indicating that the effect of citrate depends on the presence of additional nutrients.

[0172] III. Acute effects of citrate and pyruvate during epileptic seizures and ketogenic diet-like conditions

[0173] To assess the role of citrate and pyruvate in epileptic seizures and ketogenic diet-like conditions, one hour before hippocampal operation, a batch of cells was switched to a medium containing low (1 mM) glucose, 500 μM bHB, and low (0.1 mM) Mg. 2+ , HBSS medium (a nutrient-deprived medium) containing 1 mM citrate or 1 mM pyruvate ( Figure 6 During the hippocampal run, the ketone β-hydroxybutyrate (bHB) was included at a concentration of 500 μM to simulate the nutrient environment of a ketogenic diet. This bHB concentration corresponds to the circulating bHB concentration of a mild ketogenic diet (such as a modified Atkins diet).

[0174] For hippocampal assays run under seizure and ketogenic diet-like conditions, cells were then cultured in a medium containing low (0.1 mM) Mg 2+ and incubated in HBSS medium with one of the following supplements:

[0175] i) 1 mM glucose (control medium),

[0176] ii) 500 μM bHB,

[0177] iii) 500 μM bHB plus 1 mM citrate,

[0178] iv) 500 μM bHB plus 1 mM pyruvate or

[0179] v) 500 μM bHB containing 1 mM citrate plus 1 mM pyruvate.

[0180] Compared with control medium, the addition of 500 μM bHB did not affect mitochondrial respiration and ATP production at baseline, or the maximal mitochondrial respiration capacity induced by FCCP ( Figure 6 A, 6B, 6D).

[0181] OCR-bHB and pyruvate or citrate

[0182] Compared with the control medium, the addition of 500 μM bHB and 1 mM pyruvate to the culture medium increased total (especially glycolytic) ATP production by about 100% (**P<0.01). In addition, basal respiration was increased by about 50% compared with the control medium ( Figure 6 B), and increased the FCCP-driven maximal respiratory capacity by approximately 100% (**P < 0.01; Figure 6 D), but did not affect oligomycin-induced proton leakage ( Figure 6 C).

[0183] Addition of 500 μM bHB and 1 mM citrate to the culture medium did not alter total, mitochondrial, or glycolytic ATP production ( Figure 4 A) Basal mitochondrial respiration ( Figure 6 B) or the maximum mitochondrial respiratory capacity induced by FCCP ( Figure 4 D).

[0184] Combination of OCR-bHB, pyruvate and citrate

[0185] However, the addition of 500 μM bHB with 1 mM pyruvate and 1 mM citrate increased total and specifically glycolytic ATP production (*P < 0.05; Figure 6 A) and FCCP-driven maximum respiratory capacity (#P = 0.09; Figure 6 D) produced an additive gain. Thus, citrate enhanced the pyruvate-induced gain in ATP production and respiratory capacity of neurons and glia under seizure and ketogenic diet-like conditions in a more than additive manner. Statistical analysis was performed by nonparametric Mann-Whitney test with 5 replicates per condition. Figure 6 B-6D was corrected for non-mitochondrial oxygen consumption determined by the addition of rotenone and antimycin A.

[0186] Overall, Figure 6 The data in show that pyruvate dramatically increases basal (mitochondrial and glycolytic) ATP production, basal mitochondrial respiration, and FCCP-induced maximal mitochondrial respiration capacity in glial cells under epileptic seizure and ketogenic diet-like conditions. In addition, Figure 6 The data in show that citrate acutely enhances the effects of pyruvate on ATP production and mitochondrial respiration under seizure and ketogenic conditions in a more than additive manner.

[0187] ECAR measurement

[0188] The ECAR measurements were obtained simultaneously with the OCR measurements described above and are shown in Figure 6 For the hippocampal runs, cells were incubated as described above in HBSS medium containing low (0.1 mM) Mg2+, 1 mM glucose, 500 μM bHB, and 1 mM citrate, or 1 mM pyruvate or 1 mM citrate plus 1 mM pyruvate. These incubations were compared to incubations in otherwise identical medium without the addition of bHB, citrate, or pyruvate (“control 0.1 mM Mg2+”). 2+ ”) for comparison. Addition of 500 μM bHB to the culture medium did not alter the baseline or maximum glycolytic rates compared to the control medium ( Figure 7A, 7C) or baseline glycolytic ATP production ( Figure 6 A).

[0189] ECAR-bHB and pyruvate

[0190] Compared with control medium, the addition of 500 μM bHB and 1 mM pyruvate to the medium increased basal glycolytic ATP production by approximately 100% (**P < 0.01; Figure 6 A). In addition, basal glycolysis was increased by approximately 50% compared with the control medium (**P < 0.01; Figure 7 A), and increased the maximum glycolytic capacity driven by FCCP by approximately 100% (**P < 0.01; Figure 7 C).

[0191] ECAR-bHB and citrate

[0192] Compared with control medium, the addition of 500 μM bHB and 1 mM citrate did not alter basal glycolytic ATP production ( Figure 6 A) Basic glycolysis ( Figure 7 A) or maximum glycolytic capacity ( Figure 7 C).

[0193] Combination of ECAR-bHB, pyruvate, and citrate

[0194] However, the addition of 1 mM citrate to the culture medium in addition to 500 μM bHB and 1 mM pyruvate increased basal glycolytic ATP production compared with the addition of 500 μM bHB and 1 mM pyruvate (*P < 0.05; Figure 7 A) and the maximum glycolytic capacity driven by FCCP (#P = 0.056; Figure 7 C) produces an additional gain. Thus, citrate enhances in a more than additive manner the gain in basal glycolytic ATP production and maximal glycolytic capacity obtained with pyruvate in neurons and glia during seizure and ketogenic diet-like conditions.

[0195] In summary, these results show that pyruvate increases glycolysis, respiration and ATP production in glial cells under epileptic seizure and ketogenic diet-like conditions, and citrate enhances this effect. Therefore, providing pyruvate alone or in combination with citrate helps neurons and glial cells meet their energy requirements for epileptic seizures and maintain vitality. By improving cell viability, the progressive transformation of normal neuronal networks to epileptic networks (repeated epileptic seizures) is delayed, and the clinical deterioration of epileptic disorders in terms of epileptic seizure frequency, epileptic seizure severity, cognition and behavioral impairment is improved.

[0196] IV. Citrate and pyruvate in combination with additional nutrients under epileptic seizure and ketogenic diet-like conditions Long-term effects

[0197] Subsequently, we evaluated the chronic or long-term effects of pyruvate and citrate in combination with other nutrients on glycolysis, mitochondrial respiration, and ATP production in primary rat glial cell cultures under epileptic seizure and ketogenic diet-like conditions.

[0198] Glial cell cultures were cultured in a medium containing B27, high (25 mM) glucose, and high (0.8 mM) Mg. 2+ The cells were grown in a custom NBM containing B27, low (1 mM) glucose, 500 μM b-hydroxybutyrate (bHB), and low (0.1 mM) Mg2+ from DIV14 to DIV16. The reduction in glucose concentration and the addition of bHB produced the nutritional conditions of a ketogenic diet. At the same time, the reduction in Mg2+ concentration increased the neuronal firing rate, producing an epileptic seizure-like state ( Fig.12 ), and increases the cell's energy demand and production ( Fig.13 In addition, from DIV14 to DIV16, custom NBM was supplemented with test nutrients (Table 2). At DIV16, one hour before the hippocampus run, the medium was changed to a medium containing 1 mM glucose, low (0.1 mM) Mg 2+ , 500 μM bHB and Hanks' balanced salt solution (HBSS) pre-exposed to the same test nutrients from DIV14 to DIV16. The cells were left in this medium until the end of the run. Each condition was repeated six times.

[0199] Table 2. Test nutrients used during the low glucose phase and seahorse runs. X indicates no supplementation.

[0200]

[0201] Conventional neurobasal medium (NBM) lacks most of the tested nutrients, except for leucine and vitamin B3 in the form of niacin (NA). Therefore, during the low glucose phase from DIV14 to DIV16, a customized NBM lacking leucine and NA was used, i) adding leucine and NA at the desired concentrations; ii) replacing the other B3 members niacin (a combination of NA and nicotinamide (NAM)) and nicotinamide riboside (NR) with NA. The following nutrients were tested in combination (expressed as the entire combination) using the concentrations shown in Table 1: anaplerotic citrate (Citr) and pyruvate (Pyr); leucine (Leu); ω3 polyunsaturated fatty acids (w3-PUFA) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA); short chain fatty acid butyrate (C4); and vitamin B3 member NR. To assess the individual contributions of these nutrients, the entire combination was also tested without anaplerotic agents (Citr+Pyr), or Leu, or butyrate (C4), or ω3-PUFAs (DHA+EPA), or with niacin (NA+NAM, in a 1:1 ratio) in exchange for NR. DHA and EPA were coupled to bovine serum albumin (BSA) to solubilize them in the culture medium and facilitate their uptake by cells.

[0202] Since the concentrations of Leu and B3 (NA) in conventional NBM are much higher than in human blood, they were applied at physiological concentrations. Likewise, all other nutrients in the entire combination were applied at normal circulating concentrations. To exclude the effect of reducing the concentrations of Leu and NA in NBM on cell viability, we compared cells fed with high levels of Leu and NA in conventional NBM with cells fed with low levels of Leu and NA in customized NBM and with cells not fed with Leu and NA in NBM.

[0203] OCR during epileptic seizures and ketogenic diet-like conditions

[0204] In glial cell cultures under chronic epileptic seizure and ketogenic diet-like conditions, the entire combination of test nutrients consisting of anaplerotic agents according to Table 1 with 250 μM pyruvate and 250 μM citrate, w3-PUFA (2.5 μM DHA and 2.5 μM EPA), butyrate (4 μM), Leu (400 μM), and NR (10 μM) significantly increased basal (mitochondrial and glycolytic) ATP production and respiration by approximately 100% ( 1.2 ng / mL) compared to conventional NBM containing 800 μM Leu and 33 μM NA (High Leu, High NA condition). Figure 8 A, 8B), and increased the maximum respiratory capacity induced by FCCP by approximately 200% ( Figure 8 D), but did not affect oligomycin-induced proton leakage ( Figure 8 C).

[0205] These responses were primarily driven by anaplerotic agents, as basal ATP production was no longer observed in the absence of anaplerotic agents in the entire composition ( Figure 8 A) Basic breathing ( Figure 8 B) and maximum breathing capacity ( Figure 8 D) increase.

[0206] The total combination with 10 μM NR exchanged for 10 μM niacin (*P=0.051) and the absence of Leu (+P=0.12) achieved a 30%-40% reduction in the maximum respiratory capacity induced by FCCP compared to the total combination containing these components ( Figure 8 D). When the culture medium (HBSS) does not have Leu or B3 (so-called no test nutrient conditions) or has Leu or B3 (high Leu, high NA conditions; low Leu, low NA conditions), the maximum respiratory capacity induced by FCCP is the same. Therefore, neither the classic vitamin B3 nor Leu itself will have an effect on maximum respiration. However, when Leu is removed from the entire combination or when NR is replaced with niacin in the entire combination, it is surprising to see a significant decrease in maximum respiration relative to the entire combination. This is not expected because maximum respiration is not affected by their presence or absence at low or high concentrations in the HBSS culture medium. Therefore, Leu and NR have a surprising synergistic effect in the entire combination. This illustrates that leucine and NR enhance the gain in maximum respiratory capacity achieved with pyruvate and citrate in the entire combination of nutrients. At the same time, the absence of butyrate and w3-PUFA in the entire combination does not change mitochondrial respiration or ATP production ( Figure 8 A, 8B, 8D). Therefore, the complete response to the entire combination is driven by anaplerotic agents, with some enhancement by Leu and NR.

[0207] Deprivation of Leu and niacin in NBM (low Leu, low NA conditions, no test nutrient conditions) had no significant effect on respiration or ATP production. ****P<0.0001; *P=0.051; +P=0.12 relative to regular NBM (high Leu, high NA conditions) by nonparametric one-way ANOVA followed by Dunnett's multiple comparison test; #P<0.01 relative to regular NBM (high Leu, high NA conditions) by t-test; Panels B-D were corrected for non-mitochondrial oxygen consumption determined by addition of rotenone and antimycin A.

[0208] In summary, pyruvate and citrate in the whole combination increased mitochondrial ATP production and respiration at baseline, as well as maximal respiratory capacity in neurons and glial cells under epileptic seizure and ketogenic diet-like conditions. In addition, leucine and NR (exchange for niacin (NA plus NAM)) were found to enhance the gain in maximal respiratory capacity achieved with pyruvate and citrate in the whole combination.

[0209] ECAR seizures and ketogenic diet-like conditions

[0210] The same experiment was also conducted under chronic epileptic seizure and ketogenic diet-like conditions using different combinations of test nutrients according to Table 1. Figure 8 The OCR measurements shown in Figure 2 were performed simultaneously with the ECAR measurements. The entire combination of tested nutrients significantly increased the glycolytic rate by approximately 25% over the baseline compared to the conventional NBM containing 800 μM Leu and 33 μM NA (high Leu, high NA condition). Fig. 9 A), and increased by about 30% after maximal stimulation with FCCP ( Fig. 9 C). This response is driven by the anaplerotic substances pyruvate and citrate, since basal glycolysis is no longer observed in the absence of anaplerotic substances in the entire composition ( Fig. 9 A) or maximum glycolytic capacity ( Fig. 9 C) increase.

[0211] Meanwhile, the absence of butyrate, w3-PUFA, Leu, or NR exchange for niacin in the entire combination did not result in significant changes in glycolytic activity.Thus, pyruvate and citrate in the entire nutrient combination mediated increases in baseline and maximal glycolytic activity in neurons and glia under chronic epileptic seizure and ketogenic diet-like conditions.

[0212] In conclusion, Figure 8 and Fig. 9 The data presented in prove that the combination of pyruvate and citrate increases glycolysis, respiration and ATP production in glial cells under epileptic seizures and ketogenic diet-like conditions, and Leu and NR enhance these effects. Therefore, the nutrient combination containing pyruvate, citrate, Leu and NR helps neurons and glial cells to cope with the energy requirements of repeated epileptic seizures and maintain vitality. Therefore, this nutrient combination will delay the conversion of normal neuronal networks to epileptic networks (repeated epileptic seizures) and improve the clinical course of epilepsy in terms of epileptic seizure frequency, epileptic seizure severity, cognition and behavioral impairment.

[0213] V. Effects of pyruvate and citrate on cell death protection

[0214] To determine whether pyruvate and citrate protect neurons and glial cells from cell death induced by chronic electrical overstimulation. To assess protection from cell death induced by repeated overstimulation, primary mouse glial cell cultures were assayed. Glial cell cultures were prepared as described above and grown to DIV14. From DIV14 to DIV17, they were switched to medium containing B27, low (2.5 mM) glucose, and low (0.1 mM) Mg. 2+ or high (0.8 mM) Mg 2+ NBM. In the presence of low (0.1 mM) Mg 2+ Incubation in the culture medium increases the neuron discharge rate, thus producing a chronic overstimulation state. From DIV14 to DIV17, test nutrients (pyruvate or citrate) are provided by the culture medium. At DIV17, the nucleus is stained with Hoechst dye, and co-immunolabeled for NeuN (a kind of protein only found in the neuron nucleus). The nuclear shrinkage (sign of cell death) of neurons and non-neuronal nuclei is scored by high-content imaging.

[0215] Cell death assessment

[0216] To assess cell death by high-content imaging, cells were fixed in 1% formaldehyde at DIV17, permeabilized with ethanol, and incubated with a rabbit polyclonal IgG antibody against NeuN (a neuron-specific protein localized to the nucleus), followed by detection with a secondary anti-rabbit IgG antibody linked to a red fluorescent marker. Neuronal and non-neuronal nuclei were then counterstained with the blue fluorescent nuclear dye Hoechst. Nuclei were counted by a high-content imager based on signal intensity and size. A cutoff value was applied to exclude low signal intensity objects that were considered noise. Then, a cutoff value was applied to exclude areas below 30 μM that were considered cell debris. 2 Objects with an area higher than 300 μM were considered as cell masses. 2 The target is set to 60 μM 2 to distinguish the nuclei from living cells and dead cells. 2 to 60μM 2 The object area counts are from the nuclei of dead cells, while 60 μM 2 Up to 300 μM 2 The object area counts were cell nuclei from live cells. Counts were performed at 20x magnification on a fixed number of light fields per well. The counts of cell nuclei from dead neurons or dead cells were correlated to the number of live neurons or live cells, respectively, in the same well.

[0217] From DIV14 to DIV17, glial cell cultures were supplemented with 1 mM citrate. At DIV17, total cell death and neuron-specific cell death were quantified by high-content imaging. The total number of Hoechst-positive objects or NeuN-positive objects was equal between groups before applying signal intensity and area size cutoffs ( Fig.10 A, 10D).

[0218] Chronic overstimulation from DIV14 to DIV17 increased the dead cell count by approximately 7% from approximately 18% in 0.8 mM Mg2+ medium to 0.1 mM Mg 2+ About 25% of the culture medium ( Fig.10 C). The number of living cells did not decrease or decreased only slightly ( Fig.10 B), which may be due to compensatory cell proliferation.

[0219] Effects of citrate on cell death

[0220] Citrate supplementation resulted in a small increase in dead cell counts of approximately 4%, which was consistent with the increase in dead cell counts from high Mg 2+ medium increased to about 23% in low Mg2+ medium ( Fig.10 C), but did not affect the viable cell count ( Fig.10 B) Chronic overstimulation increased the number of dead neurons by about 0.4%, from high Mg 2+ The Mg content in the medium increased from about 1.4% to about 1.8% in the low Mg2+ medium ( Fig.10 F). Citrate supplementation completely blocked the increase in neuronal death from high Mg 2+ About 1.5% to low Mg in culture medium 2+ About 1.4% in the culture medium ( Fig.10 F) The total number of living neurons in low and high Mg 2+ There were no significant differences between the cultures ( Fig.10 E) In conclusion, citrate protects neurons and glial cells from excitotoxic cell death induced by chronic overstimulation.

[0221] Effects of pyruvate on cell death

[0222] The same assessment was performed with glial cells supplemented with 1 mM pyruvate. Here too, the total number of Hoechst-positive objects or NeuN-positive objects was equal between groups before applying signal intensity or area size cutoffs ( Fig.11 A, 11D). Chronic overstimulation from DIV14 to DIV17 increased the dead cell count by about 7%, from about 18% in 0.8 mM Mg2+ medium to 0.1 mM Mg2+ medium. 2+ About 26% ( Fig.11 C). The number of living cells did not decrease or decreased only slightly ( Fig.11 B) Pyruvate supplementation resulted in a small but significant increase in dead cell counts of approximately 1%, which was not observed in the high Mg 2+ medium increased to about 19% in low Mg2+ medium ( Fig.11 C), but did not affect the viable cell count ( Fig.11 B). Chronic overstimulation increased the number of dead neurons by approximately 0.4% from 0.8 mM Mg 2+ About 1.4% in the culture medium increased to 0.1mMMg 2+ About 1.8% ( Fig.11 F) Pyruvate supplementation blocks and even reduces neuronal death from high Mg 2+ About 1.5% to low Mg in culture medium 2+ About 1.4% in the culture medium ( Fig.11 F). The total number of viable neurons was not significantly different between low and high Mg2+ medium ( Fig.11 E).

[0223] In conclusion, both citrate and pyruvate protect neurons and glial cells from excitotoxic cell death induced by chronic hyperexcitability.

[0224] VI. Network Excitability

[0225] It was then demonstrated that switching glial cell cultures from high (0.8 mM) Mg 2+ Medium was switched to low (0.1 mM) Mg 2+ Electrical stimulation of neuronal networks in culture media resulted in network reorganization and greater network excitability. Electrical stimulation of neurons resulted in Ca 2+ Into the neuron, Ca 2+ Triggers the synaptic release of neurotransmitters to propagate action potentials. 2+ After influx, Ca is immediately exported from the cell. 2+ The influx and outflow of Ca2+ in the cell culture oscillates. 2+ The sum of the oscillations is a measure of the electrical activity of the entire neuronal network. Under recurrent seizures, electrical signals are transmitted more frequently and to more neurons through the network. This is due to a network reorganization driven by each seizure and that promotes the generation, transmission, and eventual synchronization of electrical signals between neurons. It manifests as an increase in the frequency and / or amplitude of Ca2+ oscillations. To determine this change in network excitability, we used a previously published assay (Pacico N et al. PLOS ONE [Public Library of Science · ONE] 2012) using Ca2+ oscillations. 2+ Sensing dyes monitor Ca 2+ oscillation.

[0226] Neurons and glial cells were isolated from embryonic day 18 mouse cortices and seeded in 96-well plates. They were then cultured in a 96-well plate containing B27, 25 mM glucose, and 0.8 mM Mg. 2+ The cells were grown in neurobasal medium (NBM) from DIV0 to DIV14. From DIV14 to DIV17, they were switched to medium containing B27, 2.5 mM glucose and low excitatory 0.1 mM Mg 2+ or high non-excitatory 0.8 mM Mg 2+ At DIV17, one hour before measurement, cells were switched to NBM containing Ca 2+ Sensitive fluorescent dye, 5mM glucose and 0.8mM Mg 2+ The cells were kept in this medium until the end of the measurement.

[0227] Pre-exposure to high non-excitatory (0.8 mM) Mg from DIV14 to DIV17 2+ Compared with glial cell cultures grown in culture medium, long-term pre-exposure to low excitatory (0.1 mM) Mg from DIV14 to DIV17 2+ Glial cell cultures in culture showed Ca 2+ The oscillation frequency increased significantly (*P<0.05; Fig.12 A, 12B), while the amplitude does not change ( Fig.12 C) Long-term pre-exposure to low Mg due to increased frequency 2+ The culture medium tends to increase Ca 2+ The area under the curve (AUC) of the oscillation Fig.12 D) shows the Ca flow into and out of the cell 2+ Therefore, glial cell cultures were chronically exposed to low (0.1 mM) Mg 2+ The culture medium resulted in a permanent increase in the excitability and activity of neuronal networks.

[0228] To assess the acute effects of neural excitation on energy demand, 0.8 mM Mg 2+ Glial cell cultures grown in a high non-excitatory medium were acutely exposed to low excitatory Mg 2+ culture medium (0.1 mM). Basal (mitochondrial and glycolytic) ATP production was observed ( Fig.13 A) Basic breathing ( Fig.13 B) and basal glycolysis ( Fig.13 E) increases, demonstrating a net increase in energy production. 2+ Acute incubation in culture medium did not alter the FCCP-induced maximum respiratory capacity ( Fig.13D) and maximum glycolytic capacity ( Fig.13 G). Therefore, from the high excitability Mg 2+ Change the medium to low excitatory Mg 2+ The culture medium dramatically increased baseline glycolysis and mitochondrial energy production in neurons and glial cells.

Claims

1. A neuroprotective composition comprising a therapeutically effective amount of a combination of pyruvate and citrate for use in treating and / or preventing neuronal damage in a subject suffering from or at risk of epileptic seizures.

2. The neuroprotective composition for use according to claim 1, wherein the treatment and / or prevention of neuronal damage comprises preventing and / or treating neuroinflammation, preventing and / or delaying the formation of epileptiform circuits in the brain.

3. Neuroprotective composition for use according to claims 1 and 2, wherein the treatment and / or prevention of neuronal damage involves increasing the metabolic activity of neurons and glial cells in the brain, preferably glycolysis and mitochondrial oxygen consumption rate.

4. Neuroprotective composition for use according to the preceding claim, wherein the treatment and / or prevention of neuronal damage comprises reducing excitotoxicity associated with or following an epileptic seizure.

5. The neuroprotective composition for use according to the preceding claims, wherein the subject suffering from or at risk of epileptic seizures is a subject suffering from stroke, traumatic brain injury, migraine, epilepsy, Alzheimer's disease, Parkinson's disease or a disorder that impairs neuronal and glial energy metabolism, including glucose transporter type 1 (Glut1) deficiency, pyruvate dehydrogenase (PDH) deficiency, glycogen storage diseases and mitochondrial diseases.

6. The neuroprotective composition for use according to the preceding claim, wherein the composition further comprises one or more compounds selected from leucine and nicotinamide riboside.

7. A neuroprotective composition for use according to the preceding claim, wherein the subject suffering from or at risk of epileptic seizures is on a ketogenic diet, preferably a ketogenic diet with a ketogenic ratio between 1:1 and 4:

1.

8. A neuroprotective composition for use according to the preceding claim, wherein the composition is a supplement to a ketogenic diet.

9. A neuroprotective composition for use according to the preceding claim, wherein the composition is a supplement to ketogenic tube feeding.

10. The neuroprotective composition for use according to claims 7 to 9, wherein the neuroprotective composition is administered to the subject suffering from or at risk of epileptic seizures and provided with between 0.1 mg and 18 mg citrate in grams citrate / kcal of the ketogenic diet and between 15 mg and 25 mg pyruvate / kcal of the ketogenic diet.

11. The neuroprotective composition for use according to claim 10, further providing nicotinamide riboside in an amount ranging from 0.01 mg to 0.4 mg / kcal of a ketogenic diet, and / or leucine in an amount ranging from 0.02 mg to 30 mg / kcal of a ketogenic diet.

12. A neuroprotective composition for use according to the preceding claims, wherein Citrate is present in the neuroprotective composition in an amount to provide a daily dosage of 0.01 g to 0.7 g / kg body weight / day; Pyruvate is present in the neuroprotective composition in an amount to provide a daily dosage of 0.15 g to 1 g per kg of body weight per day; and Optionally, nicotinamide riboside is present in the neuroprotective composition in an amount to provide a daily dosage of 0.5 mg to 15 mg per kilogram of body weight per day; And optionally, leucine is present in the neuroprotective composition in an amount to provide a daily dosage of 3 mg to 30 mg per kg body weight per day.